European Cancer Congress 2015

Oncology Meeting Resources

25 Sep - 29 Sep 2015, Vienna, Austria

ECC 2015

The European Cancer Congress (ECC 2015) combined the efforts of the most important European oncology professionals with the aim of improving the prevention, diagnosis, treatment and care of cancer patients. Partner organisations included: ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE representing a multidisciplinary approach to cancer treatment and care.

Here, ESMO members will find a selection of webcasts from the European Cancer Congress 2015. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful links





Format available

Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI

https://oncologypro.esmo.org/Meeting-Resour...r-patients-as-measured-by-DCE-MRI-and-DW-MRI

Date: 26 Sep 2015
Presenter: Nayak, N.
Resources: Webcast
Topic: Drug Development

LATE BREAKING ABSTRACT: Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé Program

https://oncologypro.esmo.org/Meeting-Resour...nd-children-The-French-national-AcSe-Program

Date: 26 Sep 2015
Presenter: Vassal, G.
Resources: Webcast
Topic: Drug Development

Discussant 18

https://oncologypro.esmo.org/Meeting-Resources/European-Cancer-Congress-2015/Discussant-18

Date: 26 Sep 2015
Presenter: Kerr, K.
Resources: Webcast
Topic: Drug Development

Discussant 19

https://oncologypro.esmo.org/Meeting-Resources/European-Cancer-Congress-2015/Discussant-19

Date: 26 Sep 2015
Presenter: Raymond, E.
Resources: Webcast
Topic: Drug Development

Influencing sorafenib disposition by blocking hepatocellular sorafenib-glucuronide uptake with rifampin in mice and humans

https://oncologypro.esmo.org/Meeting-Resour...nide-uptake-with-rifampin-in-mice-and-humans

Date: 26 Sep 2015
Presenter: Bins, S.
Resources: Webcast
Topic: Drug Development

First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors

https://oncologypro.esmo.org/Meeting-Resour...49076-in-patients-with-advanced-solid-tumors

Date: 26 Sep 2015
Presenter: Azaro, A.
Resources: Webcast
Topic: Drug Development

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors

https://oncologypro.esmo.org/Meeting-Resour...ertib-in-patients-with-advanced-solid-tumors

Date: 26 Sep 2015
Presenter: De Weger, V.
Resources: Webcast
Topic: Drug Development

Discussant 20

https://oncologypro.esmo.org/Meeting-Resources/European-Cancer-Congress-2015/Discussant-20

Date: 26 Sep 2015
Presenter: Plummer, R.
Resources: Webcast
Topic: Drug Development

A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors

https://oncologypro.esmo.org/Meeting-Resour...Preliminary-activity-in-INI1-negative-tumors

Date: 26 Sep 2015
Presenter: Italiano, A.
Resources: Webcast
Topic: Drug Development

Discussant 12

https://oncologypro.esmo.org/Meeting-Resources/European-Cancer-Congress-2015/Discussant-12

Date: 26 Sep 2015
Presenter: Beets, G.
Resources: Webcast
Topics: Colon Cancer, Rectal Cancer